연구성과로 돌아가기

2021 연구성과별 연구자 정보 (741 / 2991)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Lee, Dong-Hun Lee, DH 10 Univ Connecticut, Dept Pathobiol & Vet Sci, Storrs, CT 06269 USA David.Swayne@USDA.GOV;
Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Spackman, Erica Spackman, E 11 ARS, USDA, US Natl Poultry Res Ctr, 934 Coll Stn Rd, Athens, GA 30605 USA David.Swayne@USDA.GOV;
Efficacy of two vaccines against recent emergent antigenic variants of clade 2.3.2.1a highly pathogenic avian influenza viruses in Bangladesh Swayne, David E. Swayne, DE 12 교신저자 ARS, USDA, US Natl Poultry Res Ctr, 934 Coll Stn Rd, Athens, GA 30605 USA AAP-7166-2020 Swayne, David David.Swayne@USDA.GOV;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Gordon, Stuart C. Gordon, SC 1 Henry Ford Hlth Syst, Detroit, MI USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Trivedi, Palak Trivedi, P 2 Univ Hosp Birmingham, Birmingham, W Midlands, England ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Bowlus, Christopher Bowlus, C 3 Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA N-9276-2016 Bowlus, Christopher ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Michael, Galambos Michael, G 4 Digest Healthcare Georgia, Atlanta, GA USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Goel, Aparna Goel, A 5 Stanford Hosp, Stanford, CA USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Gulamhusein, Aliya Gulamhusein, A 6 Toronto Gen Hosp, Toronto, ON, Canada ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Levy, Cynthia Levy, C 7 Univ Miami, Miami, FL USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Neff, Guy Neff, G 8 Covenant Res, Sarasota, FL USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Stanca, Carmen Stanca, C 9 NYU Langone Hlth, New York, NY USA ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Thorburn, Douglas Thorburn, D 10 Royal Free Hosp, London, England ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Bacon, Bruce Bacon, B 11 St Louis Univ, Sch Med, St Louis, MO USA AAD-6897-2021 Simona, Gheorghe ychoi@cymabay.com;
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies Borg, Brian Borg, B 12 Jackson Liver & GI Specialists, Jackson, MS USA A-5512-2011 Borg, Brian ychoi@cymabay.com;
페이지 이동: